Bio Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Currently in Phase human trial.
Quote | Bio-Path Holdings Inc. (NASDAQ:BPTH)
|Last Trade Date Time:||12/01/2023 03:00:00 am|
News | Bio-Path Holdings Inc. (NASDAQ:BPTH)
2023-11-15 17:28:05 ET Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript November 15, 2023, 08:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price - SVP of Finance, Accounting and Administration...
2023-11-15 07:12:43 ET More on Bio-Path Seeking Alpha’s Quant Rating on Bio-Path Historical earnings data for Bio-Path Financial information for Bio-Path For further details see: Bio-Path GAAP EPS of -$0.32 beats by $0.02
Message Board Posts | Bio-Path Holdings Inc. (NASDAQ:BPTH)
|znewcar1: ML1.27 YH2.28 back under Feb? $BPTH||znewcar1||investorshangout||01/27/2023 6:37:54 PM|
|znewcar1: ML3.55 LOD3.57 Don't think $3 will hold||znewcar1||investorshangout||09/16/2022 7:05:58 PM|
|whytestocks: $BPTH News Article - Bio-Path Holdings to Announce Second Quarter 2022 Financial Result||whytestocks||investorshangout||08/09/2022 11:00:54 PM|
|Anyway, pps has been climbing slowly & steadily||cfoofme||investorshub||07/09/2022 6:57:47 PM|
|Anyone here still holding BPTH?||cfoofme||investorshub||07/08/2022 11:30:11 PM|
News, Short Squeeze, Breakout and More Instantly...
Bio-Path Holdings Inc. Company Name:
BPTH Stock Symbol:
Bio-Path Holdings Inc. Website:
Shares of UP Fintech Holding Limited (NASDAQ: TIGR) surged in pre-market trading after the company results for the third quarter. UP Fintech Holdi...
HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial result...
The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...